BRPI0516872A - uso de compostos orgánicos - Google Patents
uso de compostos orgánicosInfo
- Publication number
- BRPI0516872A BRPI0516872A BRPI0516872-4A BRPI0516872A BRPI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A
- Authority
- BR
- Brazil
- Prior art keywords
- organic compounds
- calcitonin
- relates
- patients
- specifically
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title abstract 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 3
- 102000055006 Calcitonin Human genes 0.000 abstract 2
- 108060001064 Calcitonin Proteins 0.000 abstract 2
- 229960004015 calcitonin Drugs 0.000 abstract 2
- 230000008468 bone growth Effects 0.000 abstract 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 108010068072 salmon calcitonin Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0422644.5A GB0422644D0 (en) | 2004-10-12 | 2004-10-12 | Organic compounds |
| PCT/EP2005/010892 WO2006040114A1 (en) | 2004-10-12 | 2005-10-10 | Use of organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516872A true BRPI0516872A (pt) | 2008-09-23 |
Family
ID=33443790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516872-4A BRPI0516872A (pt) | 2004-10-12 | 2005-10-10 | uso de compostos orgánicos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090048157A1 (https=) |
| EP (1) | EP1802328A1 (https=) |
| JP (1) | JP2008515947A (https=) |
| KR (1) | KR20070061864A (https=) |
| CN (1) | CN101035556A (https=) |
| AU (1) | AU2005293802A1 (https=) |
| BR (1) | BRPI0516872A (https=) |
| CA (1) | CA2580766A1 (https=) |
| GB (1) | GB0422644D0 (https=) |
| MX (1) | MX2007004259A (https=) |
| RU (1) | RU2007117492A (https=) |
| TW (1) | TW200628168A (https=) |
| WO (1) | WO2006040114A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006318815B2 (en) | 2005-11-17 | 2010-08-19 | Novartis Ag | Pharmaceutical composition |
| ES2622877T3 (es) | 2009-01-22 | 2017-07-07 | Keybioscience Ag | Tratamiento para la obesidad |
| US9533022B2 (en) | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
| EP3357540A1 (en) * | 2011-11-02 | 2018-08-08 | KeyBioscience AG | Combination of calcitonin mimetic and insulin sensitizer |
| US9006172B2 (en) * | 2011-11-02 | 2015-04-14 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
| CN107345965A (zh) * | 2016-05-04 | 2017-11-14 | 广州优迪生物科技有限公司 | 一种同时检测N-MID和β-CTX的双标记时间分辨荧光免疫分析方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| GB9108634D0 (en) * | 1991-04-23 | 1991-06-12 | Ciba Geigy | Pharmaceutical compositions |
| EP0726075A1 (en) * | 1995-02-08 | 1996-08-14 | Therapicon Srl | Pharmaceutical non-inorganic saline solutions for endonasal administration |
| IT1282374B1 (it) * | 1996-01-31 | 1998-03-20 | Therapicon Srl | Composizioni farmaceutiche parenterali a base di calcitonine sintetiche a ph controllato con basso indice di dolorosita' |
| ES2235854T3 (es) * | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| US20040110170A1 (en) * | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
| TW200411053A (en) * | 2002-12-30 | 2004-07-01 | Ind Tech Res Inst | Nucleic acid encoding recombinant salmon calcitionin, expression vector thereof, and method for producing recombinant salmon calcitonin therewith |
-
2004
- 2004-10-12 GB GBGB0422644.5A patent/GB0422644D0/en not_active Ceased
-
2005
- 2005-10-10 CA CA002580766A patent/CA2580766A1/en not_active Abandoned
- 2005-10-10 AU AU2005293802A patent/AU2005293802A1/en not_active Abandoned
- 2005-10-10 CN CNA2005800339490A patent/CN101035556A/zh active Pending
- 2005-10-10 US US11/577,127 patent/US20090048157A1/en not_active Abandoned
- 2005-10-10 JP JP2007536066A patent/JP2008515947A/ja active Pending
- 2005-10-10 MX MX2007004259A patent/MX2007004259A/es not_active Application Discontinuation
- 2005-10-10 BR BRPI0516872-4A patent/BRPI0516872A/pt not_active IP Right Cessation
- 2005-10-10 EP EP05795076A patent/EP1802328A1/en not_active Withdrawn
- 2005-10-10 WO PCT/EP2005/010892 patent/WO2006040114A1/en not_active Ceased
- 2005-10-10 RU RU2007117492/14A patent/RU2007117492A/ru not_active Application Discontinuation
- 2005-10-10 KR KR1020077008224A patent/KR20070061864A/ko not_active Withdrawn
- 2005-10-11 TW TW094135420A patent/TW200628168A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2580766A1 (en) | 2006-04-20 |
| RU2007117492A (ru) | 2008-11-20 |
| KR20070061864A (ko) | 2007-06-14 |
| MX2007004259A (es) | 2007-05-11 |
| EP1802328A1 (en) | 2007-07-04 |
| WO2006040114A1 (en) | 2006-04-20 |
| TW200628168A (en) | 2006-08-16 |
| JP2008515947A (ja) | 2008-05-15 |
| AU2005293802A1 (en) | 2006-04-20 |
| CN101035556A (zh) | 2007-09-12 |
| GB0422644D0 (en) | 2004-11-10 |
| US20090048157A1 (en) | 2009-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
| EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
| CR9312A (es) | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
| BRPI0510043A (pt) | método de tratamento de dor neuropática usando antagonista de receptor crth2 | |
| UY32030A (es) | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" | |
| PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
| BRPI0814299B8 (pt) | preparação sólida compreendendo alogliptina e cloridreto de metformina, uso de uma preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida | |
| PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
| PL2100618T3 (pl) | Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości | |
| PT1506781E (pt) | Composicao para tratamento vaginal | |
| BRPI0517701A8 (pt) | métodos de tratamento de diabetes mellitus | |
| BRPI0514721A (pt) | uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo | |
| UY32598A (es) | Sal de abt-263 y formas en estado sólido de la misma | |
| ATE353655T1 (de) | Myo-inositol hexaphosphat zur topischen verwendung | |
| ECSP12007431A (es) | Compuestos orgánicos | |
| CY1110182T1 (el) | Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων | |
| WO2008049990A3 (fr) | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer | |
| AR052056A1 (es) | Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo | |
| CR11368A (es) | Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida | |
| BRPI0516872A (pt) | uso de compostos orgánicos | |
| AR057643A1 (es) | Lacosamida para terapia adjunta | |
| AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
| UY30769A1 (es) | Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas | |
| CL2008002884A1 (es) | Composicion farmaceutica compuesta por meloxicam o calecoxib y alopurinol; composicion farmaceutica; y uso para el control y tratamiento de la gota, la artritis gotosa y otras patologias relacionadas. | |
| CR11387A (es) | Productos quimioterapeuticos cristalinos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |